Kashiv BioSciences, LLC, a globally integrated biopharmaceutical company, has appointed Dr. Sandeep Nilkanth Athalye as its new Global Chief Executive Officer. With over 20 years of experience in strategic and…
Medidata, a brand of Dassault Systèmes and a leading provider of clinical trial solutions, has partnered with Cogstate, a leader in neuroscience solutions, to transform clinical trials and outcome measurements…
Vir Biotechnology, Inc. (Nasdaq: VIR) has released its corporate update and financial results for the third quarter ended September 30, 2024. “This quarter marked a transformative period for Vir. We…
Eli Lilly and Company (NYSE: LLY) has announced that data from the Phase 3 EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader (SERD), will be presented for the…
On the morning of October 30, Ma Xin, a member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, visited Jiangsu Hansoh, a subsidiary of…
The 2024 American Society of Nephrology (ASN) Kidney Week conference took place at the San Diego Convention Center from October 23 to 27. During this event, a post-hoc analysis of…
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has announced encouraging new data from the Phase 3 SOLARIS trial on TEV-‘749, a subcutaneous extended-release…
Teva Pharmaceuticals, the U.S. branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has released interim findings from its Phase 4 IMPACT-TD Registry study. This large-scale study sheds light…
On World Cities Day, the World Health Organization (WHO) launched a new report highlighting how urban areas can tackle the increasing challenges posed by noncommunicable diseases (NCDs) and injuries. As…
A new report titled “Refugee and Migrant Health System Review: Challenges and Opportunities for Long-Term Health System Strengthening in Uganda” was launched on October 15 by Uganda’s Ministry of Health…
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Toichi Takino; “the Company”) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2025 disclosed at…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) released its third-quarter 2024 financial and operational results, showcasing strong revenue growth and notable corporate developments. CEO Commentary on Performance and Growth “Our third-quarter performance…